Société Alnylam Pharmaceuticals, Inc. Sao Paulo
Actions
A1LN34
BRA1LNBDR003
Recherche biotechnologique et médicale
Temps Différé
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
38,3 BRL | +1,65% | -.--% | -14,22% |
Métier
Nombre d'employés: 2 100
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Ribonucleic Acid Interference Therapeutics
100,0
%
| 1 037 | 100,0 % | 1 828 | 100,0 % | +76,23% |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
69,8
%
| 616 | 59,4 % | 1 276 | 69,8 % | +107,21% |
Europe
21,8
%
| 315 | 30,4 % | 399 | 21,8 % | +26,83% |
Rest of the World
8,4
%
| 107 | 10,3 % | 153 | 8,4 % | +43,31% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Chief Executive Officer | 61 | 19/09/16 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 13/08/19 |
Piyush Sharma
CMP | Compliance Officer | - | 21/09/22 |
Chief Tech/Sci/R&D Officer | - | 01/08/17 | |
Kevin Fitzgerald
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/01/05 |
James Bilotta
CTO | Chief Tech/Sci/R&D Officer | - | 01/10/15 |
Pushkal Garg
CTO | Chief Tech/Sci/R&D Officer | 56 | 29/10/14 |
Joshua Brodsky
IRO | Public Communications Contact | - | 01/02/21 |
Investor Relations Contact | 43 | 01/09/15 | |
Eric Green
PRN | Corporate Officer/Principal | - | - |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 18/12/15 |
Charles Sigal
BRD | Director/Board Member | 72 | 22/08/22 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 10/01/19 |
Amy Schulman
CHM | Chairman | 63 | 01/07/14 |
Phillip Sharp
FOU | Founder | 79 | 14/06/02 |
Peter Kellogg
BRD | Director/Board Member | 67 | 07/03/23 |
Michael Bonney
BRD | Director/Board Member | 65 | 17/12/14 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 23/04/12 |
Colleen Reitan
BRD | Director/Board Member | 64 | 01/06/18 |
Chief Executive Officer | 61 | 19/09/16 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 126 491 778 | 125 969 953 ( 99,59 %) | 0 | 99,59 % |
Coordonnées société
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street Henri A. Termeer Square
02142, Cambridge
+617 551 8200
http://www.alnylam.comSecteur
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+49,64% | 54,63 Md | |
-4,63% | 39,92 Md | |
+37,77% | 38,82 Md | |
+16,16% | 26,86 Md | |
-12,56% | 26,22 Md | |
+25,71% | 12,21 Md | |
+2,31% | 12,16 Md | |
+27,14% | 11,94 Md | |
-11,46% | 10,74 Md |
- Bourse
- Actions
- Action ALNY
- Action A1LN34
- Société Alnylam Pharmaceuticals, Inc.